9 unchanged sentences
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
+Added: Net Settlement of Equity Awards
Our restricted stock units are subject to vesting and the underlying shares of common stock are issued when the restricted stock units vest.
In the fourth quarter of 2024, we withheld shares through net settlements (where the award holder receives the net of the shares vested, after surrendering a portion of the shares back to the Company for tax withholding) for certain restricted stock units that vested.
−Removed: The following table provides a summary of shares surrendered back to the Company for tax withholding on restricted stock units that vested under our equity incentive plans in the three months ended December 31, 2023:
+Added: Share Repurchase Programs
+Added: On February 29, 2024, the Company announced the February 2024 share repurchase program of up to $100 million in shares of common stock (the "February Share Repurchase Program").
+Added: On May 22, 2024, the Company announced the May 2024 share repurchase program of up to an additional $100 million in shares of common stock (the "May Share Repurchase Program").
+Added: On August 6, 2024, the Company announced the August 2024 share repurchase program of up to an additional $100 million in shares of common stock (the "August Share Repurchase Program," and together with the February Share Repurchase Program and the May Share Repurchase Program, the "2024 Share Repurchase Programs").
+Added: As of the year-ended December 31, 2024, the 2024 Share Repurchase Programs were completed, and no amounts remained available under the 2024 Share Repurchase Programs.
+Added: The following table provides a summary of shares surrendered back to the Company for tax withholding on restricted stock units that vested under our equity incentive plans and shares purchased as part of publicly announced programs in the three months ended December 31, 2024:
Period Total Number of Shares Repurchased (1)
5 unchanged sentences
Total shares repurchased 3,343,781 $ 15.86 3,248,298 —
−Removed: (1) Represents shares withheld on net settlements of restricted stock units that vested under our equity incentive plans.
+Added: (1) Includes share repurchases and shares withheld on net settlements of restricted stock units that vested under our equity incentive plans.
Stock Performance Graph
1 unchanged sentence
under the Securities Act or the Exchange Act.
−Removed: The graph set forth below compares cumulative total return on our common stock with the cumulative total return of the (i) S&P Health Care (Sector) and (ii) the Nasdaq Composite Index resulting from an initial investment of $100 in each and, assuming the reinvestment of any dividends, based on closing prices.
−Removed: Measurement points are from October 24, 2019 (the date our common stock began trading on Nasdaq) through December 31, 2023.
−Removed: Cumulative Total Returns since Initial Public Offering
+Added: The graph set forth below compares cumulative total return on our common stock for the last five fiscal years through the fiscal year ended December 31, 2024, with that of the (i) S&P Health Care (Sector) and (ii) the Nasdaq Composite Index.
+Added: Each index assumes an initial investment of $100 in each and, assumes the reinvestment of any dividends, based on closing prices.
+Added: Cumulative Total Returns
Company/Index 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
3 unchanged sentences
NASDAQ Composite $100.00 $143.64 $175.44 $ 116.65 $ 167.30 $ 215.22
−Removed: Use of Proceeds
−Removed: On October 29, 2019, in connection with our initial public offering (IPO), we issued and sold 6,700,000 shares of our common stock and certain of our selling stockholders offered and sold 4,800,000 shares of our common stock at a price to the public of $13.00 per share resulting in net proceeds to us of $77.6 million, after deducting the underwriting discount of $5.9 million and offering expenses of $3.6 million.
−Removed: All of the shares issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No.
−Removed: 333-233965), which was declared effective by the SEC on October 24, 2019.
−Removed: The net proceeds of $77.6 million from our IPO have been invested in investment grade, interest-bearing instruments.
−Removed: There has been no material change in the expected use of the net proceeds from our IPO as described in our final prospectus, filed with the SEC on October 25, 2019 pursuant to Rule 424(b) relating to our Registration Statement.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.